Home
Products
Learn
About
Pricing
Log In
PARN

This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.

Asset Logo

Paradigm Biopharmaceuticals Limited.

🇦🇺 ASX

👑 Overview

📈 Performance

💵 Cost

🍃 Esg

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

N/A
Annual Growth

5 years average annual capital growth

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

16
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

Paradigm Biopharmaceuticals Limited. - Ordinary Fully Paid Deferred

📈 Performance

Price History

N/A

1M

All Time

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

N/A
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🤓 Advanced information

Technical Info

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in PARN

0

📊 Total Capital Earnings

N/A

🔃 Average investment frequency

N/A

💵 Average investment amount

N/A

Last time a customer invested in PARN

N/A
PARN investor breakdown
💵 Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

👶 Age of investors

18 - 25

26 - 34

35 - 90

🙋 Legal gender of investors

Female

Male

Pearlers who invest in PARN also invest in...

Paradigm Biopharmaceuticals Limited.

PAR

Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The firm is focused on developing and commercializing pentosan polysulfate sodium (PPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, ageing, degenerative disease, infection, or genetic predisposition. PPS is a semi-synthetic drug manufactured from European beech xylans that are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). Its multiple actions of PPS are mediated by targeting both NF-kB-dependent and NF-kB-independent pathways. The firm focuses on repurposing PPS for the treatment of Osteoarthritis (OA) and bone marrow lesions (BML), mucopolysaccharidosis (MPS), chronic heart failure (CHF) and alpha-viral arthritis (Ross River Virus and Chikungunya).

📊 Share price

$0.91 AUD
Find Out More

ACDC

ACDC.AX was created on 2018-08-30 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Battery ValueChain Index (the Index).

📊 Share price

$100.01 AUD

NULL GLOBAL

NULL OTHER

NULL SMART BETA

NULL THEMATIC

NULL INDEX

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

📊 Share price

$90.18 AUD

NULL AUSTRALIA

NULL BETA

VDHG

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

📊 Share price

$57.36 AUD

NULL GLOBAL

NULL SMART BETA

Qantas Airways Ltd. provides air transportation services. The company is headquartered in Mascot, New South Wales. The firm is focused on the operation of international and domestic air transportation services, the provision of freight services, and the operation of a frequent flyer loyalty program. The firm's segments include Qantas Domestic, Qantas International, Jetstar Group and Qantas Loyalty. The Qantas Domestic, Qantas International, and Jetstar Group are engaged in passenger flying business and air cargo and express freight businesses. The Qantas Loyalty segment is engaged in the customer loyalty recognition programs. Its main business is the transportation of customers using two airline brands, which include Qantas and Jetstar. Its airline brands operate in regional, domestic and international services. The firm operates in Australia, New Zealand, South Pacific, Asia, Europe, North and South America, and Africa.

📊 Share price

$6.51 AUD

NULL AIRLINES

Want more shares? Try these...

Patriot Lithium Ltd. provides exploration services. The company is headquartered in Perth, Western Australia. The company went IPO on 2022-12-09. The firm is engaged in exploring and developing lithium projects. The Company’s projects include Keystone Project, Tinton West Project, and Wickenburg Project. The Keystone Project comprises 255 lode mining claims covering approximately 21 square kilometers (km2) of lithium prospective ground in the prolific high-grade Black Hills lithium province, South Dakota. The Tinton West Project area is located approximately 18 kilometers (km) southwest of the town of Spearfish and 72 km northwest of Rapid City. The Tinton West Project comprises 69 lode mining claims covering six (km2) of lithium prospective ground in the northwestern Black Hills of South Dakota and Wyoming. The Wickenburg Project is located in Maricopa County, Arizona, approximately 10 km south of Wickenburg and 70 km northwest of Phoenix. The Wickenburg Project comprises 347 lode mining claims covering a total area of 28 km2.

📊 Share price

$0.24 AUD

Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The firm is focused on developing and commercializing pentosan polysulfate sodium (PPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, ageing, degenerative disease, infection, or genetic predisposition. PPS is a semi-synthetic drug manufactured from European beech xylans that are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). Its multiple actions of PPS are mediated by targeting both NF-kB-dependent and NF-kB-independent pathways. The firm focuses on repurposing PPS for the treatment of Osteoarthritis (OA) and bone marrow lesions (BML), mucopolysaccharidosis (MPS), chronic heart failure (CHF) and alpha-viral arthritis (Ross River Virus and Chikungunya).

📊 Share price

$0.91 AUD